ipilimumab,nivolumab
bms
['checkmate 914', 'nivo', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'gusm', 'check,mate,914', 'rcc,(-irccs),(-srcc),(-urcc)']
in checkmate 914, nivo-ipi failed to prolong dfs in patients with rcc, and 43% discontinued treatment due to toxicities, reported at #esmo22. #rccsm #gusm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.